QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
Log in
NASDAQ:KROS

Keros Therapeutics Stock Forecast, Price & News

$57.26
-1.36 (-2.32 %)
(As of 03/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$57.09
Now: $57.26
$60.71
50-Day Range
$55.25
MA: $63.38
$71.59
52-Week Range
$19.10
Now: $57.26
$88.80
Volume78,457 shs
Average Volume118,490 shs
Market Capitalization$1.16 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Keros Therapeutics logo

Headlines

Keros Therapeutics Inc
December 13, 2020 |  reuters.com
Is KROS A Good Stock To Buy Now?
December 9, 2020 |  finance.yahoo.com
Keros Therapeutics prices equity offering at $50
November 13, 2020 |  seekingalpha.com
Keros Therapeutics proposes equity offering
November 10, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KROS
CUSIPN/A
CIKN/A
Phone617-314-6297
Employees32
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$1.16 billion
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.55 out of 5 stars

Medical Sector

413th out of 1,971 stocks

Pharmaceutical Preparations Industry

203rd out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$57.26
-1.36 (-2.32 %)
(As of 03/8/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KROS News and Ratings via Email

Sign-up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Keros Therapeutics (NASDAQ:KROS) Frequently Asked Questions

Is Keros Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Keros Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Keros Therapeutics stock.
View analyst ratings for Keros Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Keros Therapeutics?

Wall Street analysts have given Keros Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Keros Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Keros Therapeutics' next earnings date?

Keros Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Keros Therapeutics
.

How were Keros Therapeutics' earnings last quarter?

Keros Therapeutics, Inc. (NASDAQ:KROS) posted its earnings results on Tuesday, November, 10th. The company reported ($0.60) EPS for the quarter, hitting the consensus estimate of ($0.60).
View Keros Therapeutics' earnings history
.

What price target have analysts set for KROS?

4 brokerages have issued 1 year target prices for Keros Therapeutics' shares. Their forecasts range from $37.00 to $100.00. On average, they anticipate Keros Therapeutics' stock price to reach $78.00 in the next year. This suggests a possible upside of 36.2% from the stock's current price.
View analysts' price targets for Keros Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Keros Therapeutics' key executives?

Keros Therapeutics' management team includes the following people:
  • Dr. Jasbir Seehra, Pres, CEO, Treasurer, Sec. & Director (Age 66, Pay $679.14k)
  • Dr. Jennifer Lachey Ph.D., Chief Scientific Officer (Age 49, Pay $387.25k)
  • Dr. Claudia Ordonez M.D., Chief Medical Officer (Age 55, Pay $169.26k)
  • Mr. Keith C. Regnante, Chief Financial Officer (Age 51)
  • Ms. Esther Cho J.D., Head of Legal & Sec.

Who are some of Keros Therapeutics' key competitors?

What other stocks do shareholders of Keros Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Keros Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Cloudera (CLDR), CVS Health (CVS), Inovio Pharmaceuticals (INO), Iovance Biotherapeutics (IOVA), Karyopharm Therapeutics (KPTI), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Pfizer (PFE).

When did Keros Therapeutics IPO?

(KROS) raised $75 million in an initial public offering on Wednesday, April 8th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

What is Keros Therapeutics' stock symbol?

Keros Therapeutics trades on the NASDAQ under the ticker symbol "KROS."

Who are Keros Therapeutics' major shareholders?

Keros Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.94%), CHI Advisors LLC (2.15%), Northern Trust Corp (0.67%), Nuveen Asset Management LLC (0.47%), Caas Capital Management LP (0.45%) and Morgan Stanley (0.37%). Company insiders that own Keros Therapeutics stock include Claudia Ordonez, Julius Knowles and Ran Nussbaum.
View institutional ownership trends for Keros Therapeutics
.

Which institutional investors are selling Keros Therapeutics stock?

KROS stock was sold by a variety of institutional investors in the last quarter, including CHI Advisors LLC, and Renaissance Technologies LLC. Company insiders that have sold Keros Therapeutics company stock in the last year include Claudia Ordonez, and Julius Knowles.
View insider buying and selling activity for Keros Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Keros Therapeutics stock?

KROS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Caas Capital Management LP, Morgan Stanley, Nuveen Asset Management LLC, Northern Trust Corp, Federated Hermes Inc., Avidity Partners Management LP, and Bank of New York Mellon Corp.
View insider buying and selling activity for Keros Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Keros Therapeutics?

Shares of KROS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Keros Therapeutics' stock price today?

One share of KROS stock can currently be purchased for approximately $57.26.

How much money does Keros Therapeutics make?

Keros Therapeutics has a market capitalization of $1.16 billion.

How many employees does Keros Therapeutics have?

Keros Therapeutics employs 32 workers across the globe.

What is Keros Therapeutics' official website?

The official website for Keros Therapeutics is www.kerostx.com.

Where are Keros Therapeutics' headquarters?

Keros Therapeutics is headquartered at 99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER, LEXINGTON MA, 02421.

How can I contact Keros Therapeutics?

Keros Therapeutics' mailing address is 99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER, LEXINGTON MA, 02421. The company can be reached via phone at 617-314-6297 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.